ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  vemurafenib
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: GO28399, NCI-2013-01160, 2012-003144-80, NCT01739764
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CO39262, NCI-2017-00509, 2016-002482-54, NCT02908672
Leflunomide and Vemurafenib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-088, NCI-2014-00593, NCT01611675
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P1446A-05/72/12, NCI-2013-02011, NCT01841463
Decitabine, Vemurafenib, and Cobimetinib in Treating Patients with Stage IV Melanoma Who Have a BRAF Mutation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201304715, NCI-2014-00838, ML28604, NCT01876641
Vemurafenib and Pembrolizumab in Treating Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 15-131, NCI-2016-01067, NCT02818023
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTMX-M-072-001, NCI-2017-00275, NCT03013491
Anti-CSF1R Monoclonal Antibody IMC-CS, Vemurafenib, and Cobimetinib in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-030, NCI-2017-01198, NCT03101254
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Vemurafenib in Treating Patients With Stage III-IV Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ML28305, NCI-2013-00664, 2012-1048, NCT01813214
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ML28897, NCI-2014-01811, PRO 02, NCT02091141
Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and overt
Trial IDs: A071601, NCI-2017-00740, A071601
Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 12 months to 21 years
Trial IDs: APEC1621SC, NCI-2017-01251, NCT03155620
Vemurafenib with Sorafenib Tosylate or Crizotinib in Treating Patients with Advanced Malignancies with BRAF Mutations
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1183, NCI-2012-00217, NCT01531361
Vemurafenib and Recombinant Interferon alfa-2b in Treating Patients With Stage III-IV Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-107, NCI-2013-01876, PRO13040314, NCT01943422
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29475, NCI-2016-00852, NCT02608034
Hsp90 Inhibitor XL888, Vemurafenib, and Cobimetinib in Treating Patients with BRAF Mutated Stage IIIB-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18597, NCI-2016-01261, NCT02721459
Vemurafenib in Treating Younger Patients with Recurrent or Refractory BRAFV600E-Mutant Brain Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 25
Trial IDs: CC #120819, NCI-2014-00387, 076373, 092093, PNOC-002, NCT01748149
Start Over